7Larsen V.Teratogenic effects of thalidomide,imipramine HC and imipramine N-oxide HC on white Danish rabbits[J].Acta Pharmacol Toxicol,1963,20:186-200.
1[1]Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide [J]. Eur J Clin Pharmacol, 2001,57(5):365-376.
2[2]Rajkumar SV. Current status of thalidomide in the treatment of cancer [J]. Oncology (Huntingt), 2001,15(7):867-874,877-879.
3[3]Gupta D, Muller G, Anderson KC. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications [J]. Leukemia, 2001,15(12):1950-1961.
4[4]Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease [J]. Gut, 2002,50(2):196-200.
5[5]Settles B, Stevenson A, Wilson K. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide [J]. Cell Mol Biol (Noisy-le-grand), 2001,47(7):1105-1114.
6[6]Bekker LG, Haslett P, Maartens G. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis [J]. J Infect Dis, 2000,181(3):954-965.
7[7]Davies FE, Raje N, Hideshima T. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J]. Blood, 2001,98(1):210-216.
8[8]Singhal S, Mehta J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma [J]. N Engl J Med,2000,342(5):364.
9[9]Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M.The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma [J]. Hematol J,2002,3(1):43-48.
10[10]Alexanian R,Weber D.Thalidomide for resistant and relapsing myeloma [J]. Simin Hematol,2000,37(Suppl 13):22-25.
